KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.

Jessica A Bryant, Marin Vulić, Emily A Walsh, Edward G Allen, Nicholas J Beauchemin, Meghan E Chafee, Liyang Diao, Kathrin Fenn, Kara A Ford, Brooke R Hasson, Kevin D Litcofsky, Mary-Jane Lombardo, Asuncion Martinez, Edward J O'Brien, Timothy J Straub, Sean M Sykes, Lisa Faye Marshall, Jonathan A Winkler, Barbara H McGovern, Christopher B Ford, Jennifer R Wortman, Matthew R Henn

Nat Med 32(1) 186-196

PMID41491103
PMCIDPMC12823442
DOI10.1038/s41591-025-04076-w
发表日期2026-01-06
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 14 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 9 张未列出。
摘要

摘要

VOWST (VOWST oral spores, VOS; fecal microbiota spores, live-brpk, formerly SER-109) is an FDA-approved, orally administered consortium of purified Firmicutes spores developed to prevent recurrent Clostridioides difficile infection (CDI). Although 86.7% (26/30) of patients with recurrent CDI did not experience a subsequent recurrence over 8 weeks in an open-label phase 1b study, a subsequent double-blind phase 2 study ( NCT02437487 ) did not demonstrate a significant benefit over placebo (rate of recurrence at 8 weeks in SER-109 versus placebo: 44.1% versus 53.3%). These discordant outcomes were hypothesized to be due to suboptimal dosing. This hypothesis was addressed in a pivotal phase 3 trial ( NCT03183128 ) using an approximately tenfold higher dose. In phase 3, only 12% of VOS-treated patients versus 40% of placebo patients recurred by week 8 (relative risk 0.32, P < 0.001). Here in this follow-up post hoc analysis, across-trial comparisons confirmed that the higher, efficacious phase 3 dose is associated with improved pharmacokinetics, assessed by VOS engraftment (patients with available samples: phase 1b: 28, phase 2: 79, phase 3: 170). In-depth phase 3 analyses revealed that VOS significantly altered microbial composition, significantly enriching the diversity and abundance of Firmicutes species and reducing the prevalence and abundance of C. difficile and opportunistic pathogens (for example, Enterobacteriaceae species). Consistent with these taxonomic changes, significant changes in key bioactive metabolites were observed, including depletion of conjugated and deconjugated primary bile acids, enrichment of secondary bile acids and increases in short-chain and medium-chain fatty acids. In vitro, VOS batches produced these C. difficile-inhibiting metabolites. These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the phase 3 study; they also highlight the need to include the microbiome in the clinical management of CDI. ClinicalTrials.gov registrations: NCT02437487 and NCT03183128 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(14,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Clinical results and engraftment of dose species in patients receiving VOS treatment across trials. a , The percentage of patients who were recurrence free after 8 weeks is shown for the VOS (formerly SER-109) phase 1, phase 2 and phase 3 studies. Patient numbers are noted for each group. b , Box plots displaying VOS dose species engraftment quantified as newly appearing dose species, observed across the phase 1−3 (Ph1−3) clinical trials with sample numbers listed in the table below. VOS doses used across the three trials were categorized into high-dose regimens, encompassing the phase 3 study and higher dosing levels in the phase 1 dose-escalating study, and low-dose regimens, encompassing the phase 2 study and lower dosing levels in the phase 1 dose-escalating study ( Methods ). Box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each timepoint; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range); and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). NS, not significant.
非 KM Figure
Fig. 2VOS dose species richness and engraftment stratified by age or antibiotic in the phase 3 trial. Box plots display dose richness ( a ) (the number of dose species) and the number of engrafting species (defined as newly appearing dose species) ( b ) observed at baseline (post-antibiotics, pre-dosing) and 1 week after treatment, in patients younger than 65 years versus patients 65 years or older. Sample sizes for dose richness ( a ) are 31, 44, 36, 47 and 32, 39, 30, 36 for VOS < 65 years, VOS ≥ 65 years, placebo <65 years and placebo ≥65 years, at baseline and at week 1, respectively. Sample sizes for newly appearing dose species ( b ) are 31, 44, 36, 47 and 27, 38, 28, 34 for VOS < 65 years, VOS ≥ 65 years, placebo <65 years and placebo ≥65 years, at baseline and at week 1, respectively. Dose richness ( c ) and species richness ( d ) observed in patients who received vancomycin versus fidaxomicin to treat their qualifying CDI episode. Sample sizes are 55, 20, 60, 23 and 53, 18, 46, 20 for VOS vancomycin, VOS fidaxomicin, placebo vancomycin and placebo fidaxomicin at baseline and at week 1, respectively. e , Engraftment in the antibiotic subpopulations across the entire timecourse of the phase 3 trial. Sample sizes are indicated along the x axis. All box plots show the median (central horizontal line) and interquartile range (shaded box); vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range); and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P values indicate single comparisons with two-sided MWU. Note that newly appearing dose species require a paired-patient baseline sample, resulting in lower post-dosing sample sizes for this metric.
非 KM Figure
Fig. 3Compositional distances between patient microbiomes in the phase 3 trial. NMDS plot displaying Bray−Curtis dissimilarity of microbial composition between patient samples from baseline (before treatment) through 24 weeks after treatment in the phase 3 study ( k = 3, stress = 0.13), including ellipses outlining 95% confidence intervals of the bivariate normal fit to each group. A cohort of 68 healthy individuals is also plotted as a reference at the pretreatment baseline (green points) with healthy population data ellipse (green filled) projected across all timepoints. VOS (blue) and placebo (gray) sample sizes are shown in the bottom right corner, respectively. NMDS axis 3 is provided in Supplementary Fig. 2 .
非 KM Figure
Fig. 4Relative abundances of the three major gastrointestinal bacterial phyla across the phase 3 study. Box plots depict relative abundances of Firmicutes ( a ), Proteobacteria ( b ) and Bacteroidetes ( c ) phyla. Note that linear scale is used for Firmicutes ( a ) and Bacteroidetes ( c ). By contrast, Proteobacteria ( b ) is typically only a minor component of the gastrointestinal microbiome in healthy individuals and, thus, is shown using a log scale to better view the distribution of sample abundances below 1%. All box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each timepoint; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range); and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P values indicate single comparisons between treatment arms at each timepoint with two-sided MWU. Sample sizes (VOS, placebo): baseline (75, 83); week 1 (71, 66); week 2 (65, 55); week 8 (64, 46); week 24 (51, 40).
非 KM Figure
Fig. 5Prevalence of bacterial genera within each treatment arm in the phase 3 study. Letters in parentheses next to group names indicate phylum membership: (F), Firmicutes; (P), Proteobacteria; (A), Actinobacteria; (U), Fusobacteria; (B), Bacteroidetes. Genera identified in at least 30% of samples and with significant differences in prevalence between treatment arms for at least one timepoint are shown. Significant differences in prevalence between treatment arms are designated with gold stars (Fisher’s exact test, FDR < 0.05). Sample sizes (VOS, placebo): baseline (75, 83); week 1 (71, 66); week 2 (65, 55); week 8 (64, 46); week 24 (51, 40).
非 KM Figure
Fig. 6Comparison of bile acids and fatty acids across treatment arms from baseline through week 8. Box plots depict median concentration of various primary and secondary bile acids ( a ) and short-chain, medium-chain and branched-chain fatty acids ( b ) in patient stool samples. All box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each timepoint; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range); and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P values indicate single comparisons with two-sided MWU. Sample numbers for bile acids are 77, 72, 66 and 63 for VOS and 81, 66, 56 and 45 for placebo, across timepoints, respectively. Sample numbers for fatty acids are 69, 63, 59 and 56 for VOS and 67, 53, 47 and 36 for placebo, across timepoints, respectively.
非 KM Figure
Extended Data Fig. 1Phase 3 trial stool samples inclusion by treatment arm and timepoint. ( a ) Blue segments correspond to the number of subject samples available for analysis. Orange indicates samples where MGX sequencing produced fewer reads than the minimum threshold. Purple indicates samples excluded due to a trial protocol deviation. Red segments correspond to samples excluded because they were collected after an on-study recurrence. ( b ) Subjects who experienced an on-study CDI recurrence were treated with antibiotics and subsequently had lower dose richness than subjects who did not experience an on-study CDI recurrence. Box plots indicating number of dose species (dose richness) observed in subject stool samples colored by whether (Y - purple) or not (N - green) they were collected following a post-treatment recurrence. Box plots used to visualize differences in dose richness show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses indicate outlier values (outside 1.5 times the interquartile range). ( c ) Table displaying samples numbers for B. Not all subjects who experienced an on-study recurrence provided a post recurrence sample.
非 KM Figure
Extended Data Fig. 2Dose species richness and abundance across study timepoints compared to healthy in Phase 3 trial. ( a ) Box plots depict dose species richness. VOS arm was not significantly different than the healthy cohort at any timepoint (p > 0.05, two-sided Mann-Whitney U-tests) whereas placebo was consistently significantly lower than healthy (p < 0.001). ( b ) Box plots depicting the summed percentages of dose species. Compared to the healthy cohort, VOS subjects had a significantly higher relative abundance of dose species at week 1 and 2 (p < 0.01, two-sided Mann-Whitney U-tests) but not at week 8 or 24 (p > 0.05). Placebo dose species abundance was significantly lower than the healthy cohort, across all post-dosing timepoints (p < 0.001). All box plots visualizing dose richness and abundances show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses indicate outlier values (outside 1.5 times the interquartile range). Sample sizes (VOS, PBO): Baseline (75,83); Week 1 (71,66), Week 2 (65, 55), Week 8 (64, 46), Week 24 (51, 40). Healthy cohort (68).
非 KM Figure
Extended Data Fig. 3Strong and durable engraftment after VOS treatment irrespective of age in the phase 3 trial. Box plots depicting the number of newly appearing dose species (engraftment), in subjects who were less than 65 years of age or 65 years of age or older at baseline throughout the 24-week study timepoint. The number of samples analyzed for each arm and timepoint are listed in the table below the graph. All box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P-values indicate single comparisons of VOS vs placebo within each subpopulation and timepoint with two-sided Mann-Whitney U-tests.
非 KM Figure
Extended Data Fig. 4Durable strain engraftment associates with species-level engraftment in the phase 3 trial. ( a ) Fraction of the newly appearing dose species observed in each sample (see Fig. 1 ), that when analyzed with a strain-based method (StrainPhlAn) either matched a dose strain (dose strain - green), were phylogenetically distinct from dose strains (not a dose strain - pink) or were not detected in either the dose material or stool sample (no strain detected - lavender). Each vertical bar represents a single sample. Samples are sorted by fraction of dose strains. ( b ) Box plots indicating the number of newly appearing dose species confirmed to be dose strains using the StrainPhlAn algorithm. Box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P-values indicate single comparisons of VOS vs placebo within each timepoint using two-sided Mann-Whitney U-tests. c ) Number of newly appearing dose species (x-axis) compared to the number of engrafting species which match dose strains (Dose Strains, y-axis). R 2 value of linear regressions modeling dose strains by newly appearing dose species for VOS and placebo samples are written in the top and bottom of plots, respectively. Shaded regions define 95% confidence interval of the model. Sample sizes (VOS, PBO): Baseline (75,83); Week 1 (71,66), Week 2 (65, 55), Week 8 (64, 46), Week 24 (51, 40).
非 KM Figure
Extended Data Fig. 5Enrichment of primary and secondary bile acids in phase 3 subject stool samples. ( a ) Volcano plot showing enrichment of primary and secondary bile acids in the VOS (Log10(Fold Changes) > 0) versus the placebo arm (Log10(Fold Change) < 0) in a global metabolomics assay across time points. The x-axis represents bile acid concentration differences, while the y-axis shows statistical significance between arms (black horizontal line, FDR < 0.05). b ) Comparison of primary conjugated bile acid concentrations observed in VOS and placebo arms across timepoints. Box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). P-values indicate single comparisons with two-sided Mann-Whitney U-tests. Sample numbers across timepoints for VOS and placebo are 39, 39, 53 and 29 and placebo are 21, 25, 15 and 14, respectively.
非 KM Figure
Extended Data Fig. 6Concentration dependent fatty acid growth inhibition. The half maximum inhibitory concentration (IC 50 [mM]) of butyrate, isovalerate, valerate and hexanoate that results in 50% reduction of OD 600 (yield) in 24 hour batch cultures of the C. difficile ribotypes (Ribotypes: R-001, ATCC 9689; R-069, ATCC 043593; R-087, ATCC 43255) in medium with mannitol or methionine & glycine at indicated pH values. Transparent bars represent IC 50 values > 80 mM, the highest concentration of fatty acid tested. Each bar represents the average of triplicate cultures.
非 KM Figure
Extended Data Fig. 7Metabolite concentrations in supernatant of dose material grown in-vitro. Cultures were run in triplicate, with black circles indicating individual values for each donor sample. Red dotted line indicates the lowest concentration in the calibration standard range (below lower limit of quantification), values below which were extrapolated. Media control is un-inoculated media samples included in growth plates. All box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses (+) indicate outlier values (outside 1.5 times the interquartile range).
非 KM Figure
Extended Data Fig. 8Metabolite concentrations in Phase 3 subject stool samples, plotted by donor batch received. Box plots indicate concentrations of various fatty acid metabolites in subject stool samples plotted by which donor batch was used to generate the VOS treatment they received. All box plots show the median (central horizontal line) and interquartile range (shaded box) in each group at each time point; vertical bars indicate the most extreme non-outlier values (within 1.5 times the interquartile range), and crosses (+) indicate outlier values (outside 1.5 times the interquartile range). Number of subjects with metabolite data that received each batch are as follows: Donor A Batch 1: 25, Donor A Batch 2: 4, Donor B: 12, Donor C: 14, Donor D: 29, Placebo: 87.
非 KM Figure